Investigating a new treatment for Alzheimer's Disease
Official title: Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD
Funded at Virogenics, INC. · NIH-10779413 · Data updated 2026-11-12
This study is testing a new drug called CMS121 to see if it can help people with mild to moderate Alzheimer's Disease by improving memory and thinking skills, while also making sure it's safe to take every day.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virogenics, INC. NIH-funded |
| Lab location | 1 site (Del Mar, United States) |
| Project start | September 24, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,594,649 |
| NIH project number | 1U01AG084549-01 |
| Project ID | NIH-10779413 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with mild to moderate Alzheimer's Disease.
✕Less likely to help
Patients with severe Alzheimer's Disease or those who do not meet the age and diagnosis criteria may not benefit from this research.
What this research studies
This research focuses on advancing a new drug called CMS121 to Phase 2 clinical trials for patients with mild to moderate Alzheimer's Disease (AD). The study involves conducting long-term non-clinical toxicology assessments to ensure the safety of daily administration of CMS121. This drug has shown promise in animal models by targeting different mechanisms than currently approved AD medications, which primarily reduce amyloid plaques. The goal is to develop a treatment that not only addresses plaque load but also improves cognitive functions such as memory and executive function.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves cognitive function and quality of life for individuals with Alzheimer's Disease.
How similar studies have gone: While CMS121 represents a novel approach, similar research has shown promise in developing new AD treatments that target multiple disease mechanisms.
Where this research is happening
-
Virogenics, INC.
Del Mar, United States Active
Researchers
- Principal investigator: Raschke, William C — Virogenics, INC.
- Study coordinator: Raschke, William C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.